DBV Technologies (DBVT) stock
Market cap $727M
Market closed. Prices as of Friday's close.
Follow DBVT's trial news. Members get an alert when DBV Technologies files news, and see its trials, share raises, and its CEO's filings.
What's next for DBVT, and how long its cash lasts
From DBV Technologies’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
For members: 2 trials underway and 42 filings.
Cash runway to Jun 30
About 4 quarters
For members: the share count, 1 raise, 2 shelf filings, and the math.
For members: their 1 filing and quote, and an alert each time they file.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why it's down
Down 28% in 3 months, 15% under its 50-day average.
Down more than its industry: the 259 other stocks in it fell a median 10% over the same 3 months.
−2Dilution 3.2 times as many shares outstanding as a year ago
4 more things pulling DBVT's score down, for members
What's next
Expected to report Wed Oct 28, after the close
After its last 4 reports it closed -2.4% on average, higher 0 of 4 times.
What would turn DBVT's score around: 9 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
Nothing is firing on DBVT right now
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How DBVT ranks in Biotech
DBVT is #224 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
- 1
TGTXTG Therapeutics8/1319
- 2
RGENRepligen7/1319
- 3
HALOHalozyme Therapeutics7/1319
EXELExelixisOpen for its score
ONCBeOne MedicinesOpen for its score
- 224
DBVTDBV Technologies0/13-5
When does DBVT report, and what happens after?
Expected to report Wed Oct 28, after the close (in 31 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Jul 16, 2026After close | After close | +1.3% | -1.1% | -6.7% |
| Apr 30, 2026After close | After close | +0.9% | -5.4% | -4.8% |
| Mar 26, 2026After close | After close | +2.8% | -1.0% | +4.2% |
| Oct 28, 2025After close | After close | -7.6% | -2.2% | -7.7% |
The gap is the next open against the close before the report; the reaction is where that session closed. DBVT closed higher after 0 of its last 4. Past behavior, not a forecast.
Report dates and past reactions come from sessions that have already closed, so none of these figures move.
About DBV Technologies
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of DBVT's score, with the points and the reason
- All 14 checks on DBVT and on all 2,950 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on DBVT
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.
The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.